Fig. 1From: Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edemaPercent change (95% CI) from baseline in excess CST at EoT visit (FAS). CI, confidence interval; CST, central subfield thickness; EoT, end of treatment; FAS, full analysis setBack to article page